Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

including POM3 treatment, in patients with hypertriglyceridemia. Moreover, results from clinical event trials are needed to assess the risks and benefits of combinations of lipid-altering ...

After oral administration of P-O3FA, in both healthy volunteers and patients with hypertriglyceridemia, EPA and DHA are well absorbed. [2] P-O3FA induced significant, dose-dependent increases in ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

Treatment for sleep apnea aims to improve your breathing during sleep and reduce the risk of underlying health concerns. Common options include CPAP machines, oral devices, and lifestyle measures ...

Pegozafermin For The Treatment Of Patients With Severe Hypertriglyceridemia As I noted above, 89bio is in the process of also exploring the use of its FGF21 analog for the treatment of patients ...